Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target Raised to $38.00

Centessa Pharmaceuticals (NASDAQ:CNTA) had its price objective upped by Truist Financial from $33.00 to $38.00 in a research note published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also commented on CNTA. Piper Sandler reiterated an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Oppenheimer lifted their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 27th. Stephens started coverage on Centessa Pharmaceuticals in a research note on Tuesday, October 28th. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Centessa Pharmaceuticals Trading Down 1.3%

Shares of NASDAQ:CNTA opened at $24.57 on Thursday. The business has a 50-day moving average price of $25.56 and a 200-day moving average price of $22.42. The stock has a market cap of $3.30 billion, a price-to-earnings ratio of -13.43 and a beta of 1.56. Centessa Pharmaceuticals has a 52-week low of $9.60 and a 52-week high of $30.58. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). Equities analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Mario Alberto Accardi sold 10,000 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the transaction, the insider directly owned 178,801 shares of the company’s stock, valued at approximately $5,364,030. The trade was a 5.30% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CTO Tia L. Bush sold 40,000 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the transaction, the chief technology officer directly owned 121,503 shares of the company’s stock, valued at $3,159,078. This represents a 24.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. TD Waterhouse Canada Inc. acquired a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $25,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after buying an additional 979 shares in the last quarter. DNB Asset Management AS acquired a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at about $218,000. Sigma Planning Corp purchased a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $225,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $218,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.